Extreme prematurity is associated with an increased risk to develop bronchopulmonary dysplasia (BPD). Severe BPD is associated with a significant long-term burden for the affected infant, families and society. Currently there are limited prevention and treatment options. Regenerative approaches using mesenchymal stromal cells (MSC) are associated with promising benefits in animal experiments. First clinical studies, using MSC in humans, suggest safety. To accelerate the process of bench to bed-side development of MSC-based therapies, a global and collaborative approach is needed that includes all key stakeholders. Results of a workshop that was held during the Pediatric Academic Societies meeting in 2019 are summarized. A roadmap is provided discussing next steps of bringing MSC-based interventions into clinical practice.

中文翻译：

---

如何将基于 MSC 的肺发育疗法安全地引入临床护理？

极端早产与发生支气管肺发育不良 (BPD) 的风险增加有关。严重的 BPD 会给受影响的婴儿、家庭和社会带来重大的长期负担。目前，预防和治疗选择有限。使用间充质基质细胞 (MSC) 的再生方法在动物实验中具有良好的益处。在人类中使用 MSC 的第一项临床研究表明是安全的。为了加速基于 MSC 的疗法从实验室到床边开发的过程，需要一种包括所有关键利益相关者在内的全球协作方法。总结了在 2019 年儿科学会会议期间举行的研讨会的结果。提供了一个路线图，讨论将基于 MSC 的干预措施引入临床实践的后续步骤。